July 28, 2015
JPA Executive Director Yoshihiro Abe The government could consider soothing the nerves of drug makers weighing investments in Japan by setting a longer-term trial period for a key price-maintenance premium , Yoshihiro Abe, executive director of the Japan Pharmaceutical Association...read more